Statin Applications in Fungal Infection Management

Statins, widely prescribed as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in cholesterol biosynthesis, have emerged as promising adjuncts in the management of fungal infections. By targeting the analogous ergosterol synthesis pathway in fungi, statins compromise cell membrane integrity, reduce fungal growth and may potentiate existing antifungal agents. Beyond direct antifungal effects, statins modulate host immune responses and induce oxidative stress within fungal cells through reactive oxygen species generation. Drug-repurposing studies have demonstrated that certain statins can convert fungistatic azoles into fungicidal combinations, overcome resistance mechanisms and improve topical and systemic delivery via advanced formulations. These multidisciplinary advances address the global burden of invasive and mucocutaneous mycoses, offering scalable strategies to counter rising resistance and expand therapeutic options for immunocompromised and vulnerable populations.

Research from Nature Portfolio

Recent studies have delineated the molecular determinants of statin action against Candida species by characterising point mutations in the catalytic domain of HMG-CoA reductase. Site-directed mutagenesis of key residues revealed their roles in substrate and statin binding, with certain mutations markedly reducing enzymatic activity and binding affinity for simvastatin. In silico analyses corroborated these findings, mapping interaction hotspots that inform the rational design of next-generation statins optimised for antifungal specificity. These insights lay the groundwork for structure-guided drug development aimed at overcoming emergent resistance.

Statin Applications in Fungal Infection Management publication trend

The graph below shows the total number of articles in statin applications in fungal infection management across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase: Enzyme that catalyses the rate-limiting step in cholesterol (in mammals) or ergosterol (in fungi) biosynthesis.

Ergosterol: Principal sterol component of fungal cell membranes, analogous to cholesterol in animal cells, essential for membrane fluidity and integrity.

Reactive oxygen species (ROS): Highly reactive molecules derived from oxygen that can damage cellular components, contributing to antimicrobial effects.

Minimum inhibitory concentration (MIC): Lowest concentration of a drug required to prevent visible growth of a microorganism under defined conditions.

References

1. Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. Antioxidants (2024).
2. Atorvastatin liposomes in a 3D-printed polymer film: a repurposing approach for local treatment of oral candidiasis. Drug Delivery and Translational Research (2023).
3. Exposure of Aspergillus fumigatus to Atorvastatin Leads to Altered Membrane Permeability and Induction of an Oxidative Stress Response. Journal of Fungi (2020).
4. Point mutations in Candida glabrata 3-hydroxy-3-methylglutaryl-coenzyme A reductase (CgHMGR) decrease enzymatic activity and substrate/inhibitor affinity. Scientific Reports (2021).